ticagrelor
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
Thousands to benefit with new anti-clotting drug recommendation, says NICE
August 12, 2016Medical Communications, Sales and Marketing AstraZeneca, Brilique, ticagrelor
The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending AstraZeneca’s Brilique (ticagrelor) for people …
AstraZeneca looks to oncology match-ups to boost sales
April 24, 2015Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor
AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
Mixed results for AstraZeneca in high-profile Brilinta study
March 17, 2015Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor
Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …
AstraZeneca’s troubled Brilinta gets welcome lift
January 14, 2015Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor
AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …
EMA questions Brilinta data
November 8, 2013Sales and Marketing Brilinta, EMA, astrazenca, heart, ticagrelor
The European Medicines Agency is demanding more information from AstraZeneca on its troubled heart pill Brilinta. This rounds off a …
Efient fails to prove superiority to Plavix
August 29, 2012Brillinta, Efient, Plavix, prasugrel, ticagrelor
Daiichi Sankyo and Lilly’s heart drug Efient has failed to come up to the mark in a late-stage trial which …
AZ’s Brilique approved in Europe
December 7, 2010Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor
European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …
Latest content
FibroFind appoints Lee Borthwick as CEO
